These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10640887)

  • 1. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty.
    Mul D; de Muinck Keizer-Schrama SM; Oostdijk W; Drop SL
    Horm Res; 1999 Dec; 51(6):270-6. PubMed ID: 10640887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial growth deceleration during GnRH analogue therapy for precocious puberty.
    Mouat F; Hofman PL; Jefferies C; Gunn AJ; Cutfield WS
    Clin Endocrinol (Oxf); 2009 May; 70(5):751-6. PubMed ID: 19178517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.
    Thaneetrakool T; Aroonparkmongkol S; Numsriskulrat N; Supornsilchai V; Wacharasindhu S; Srilanchakon K
    Front Endocrinol (Lausanne); 2024; 15():1390674. PubMed ID: 38737553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot leuprolide acetate dosage for sexual precocity.
    Parker KL; Baens-Bailon RG; Lee PA
    J Clin Endocrinol Metab; 1991 Jul; 73(1):50-2. PubMed ID: 1904452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).
    Borges Mde F; Franciscon Pde M; Cambraia TC; Oliveira DM; Ferreira BP; Resende EA; Palhares HM
    Arch Endocrinol Metab; 2015 Dec; 59(6):515-22. PubMed ID: 26421668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of leuprolide therapy in children with central precocious puberty.
    Kappy MS; Stuart T; Perelman A
    Am J Dis Child; 1988 Oct; 142(10):1061-4. PubMed ID: 3140654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
    Demirbilek H; Alikasifoglu A; Gonc NE; Ozon A; Kandemir N
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):126-30. PubMed ID: 21790701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
    Hagen CP; Sørensen K; Anderson RA; Juul A
    Fertil Steril; 2012 Nov; 98(5):1326-30. PubMed ID: 22901847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.
    Cohen D; Janfaza M; Klein KO
    J Pediatr Endocrinol Metab; 2009 Jul; 22(7):629-34. PubMed ID: 19774844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty].
    Mericq G MV; Youlton R R; Willshaw Z ME
    Rev Med Chil; 2006 Jul; 134(7):821-6. PubMed ID: 17130963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.